Substances and methods for the use in prevention and/or treatment in huntington's disease

Abstract

Disclosed is an apheresis device including a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule(s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.

1 : An apheresis device, comprising a solid carrier capable of being contacted with the blood or plasma flow, wherein the solid carrier includes a huntingtin (HTT)-binding molecule. 
     
     
         2 : The apheresis device according to  claim 1 , wherein the HTT-binding molecule is an anti-HTT antibody. 
     
     
         3 : The apheresis device according to  claim 1 , wherein the HTT-binding molecule is a monoclonal antibody or an HTT-binding fragment thereof. 
     
     
         4 : The apheresis device according to  claim 3 , wherein the HTT-binding fragment is selected from the group consisting of a Fab fragment, a Fd fragment, a Fab′ fragment, a F(ab′)2 fragment, a Fv fragment, and ScFv fragment. 
     
     
         5 : The apheresis device according to  claim 2 , wherein the antibody is a polyclonal antibody. 
     
     
         6 : The apheresis device according to  claim 2 , wherein the antibody is specific for the PRR region of HTT, the C6 region of HTT, or both. 
     
     
         7 : The apheresis device according to  claim 1 , wherein the antibody is a monoclonal antibody selected from the group consisting of a human monoclonal antibody, a humanized monoclonal antibody, a bispecific monoclonal antibody, and a chimeric monoclonal antibody. 
     
     
         8 : The apheresis device according to  claim 2 , wherein the antibody is a monoclonal antibody, which comprises a heavy chain variable region CDR1 comprising GYSFTDFY (SEQ ID No. 54), a heavy chain variable region CDR2 comprising IDPKNGDT (SEQ ID No. 55), a heavy chain variable region CDR3 comprising ATYYGYTMDY (SEQ ID No. 56), a light chain variable region CDR1 comprising SSVTSSY (SEQ ID No. 57), a light chain variable region CDR2 comprising STS (SEQ ID No. 58) a light chain variable region comprising HQYRRPPRT (SEQ ID No. 59). 
     
     
         9 : The apheresis device according to  claim 8 , wherein the antibody is the monoclonal antibody PRR13. 
     
     
         10 : The apheresis device according to  claim 2 , wherein the antibody is a monoclonal antibody, which comprises a heavy chain variable region CDR1 comprising GYTFTEYT (SEQ ID No. 66), a heavy chain variable region CDR2 comprising INPNNGGT (SEQ ID No. 67), a heavy chain variable region CDR3 comprising ASLDGRDY (SEQ ID No. 68), a light chain variable region CDR1 comprising QSLLNSRTRKNY SEQ ID No. 69),a light chain variable region CDR2 comprising WAS (SEQ ID No. 70) and a light chain variable region comprising KQSYNLLT (SEQ ID No. 71). 
     
     
         11 : The apheresis device according to  claim 10 , wherein the antibody is the monoclonal antibody C6-17. 
     
     
         12 : The apheresis device according to  claim 2 , wherein the antibody is a monoclonal antibody, which comprises a heavy chain variable region CDR1 comprising GFTFNTYA (SEQ ID No. 72), a heavy chain variable region CDR2 comprising IRSKSNNYAT (SEQ ID No. 73), a heavy chain variable region CDR3 comprising VRHGEYGNPWFAY (SEQ ID No. 74), a light chain variable region CDR1 comprising QSLVHSNGNTY (SEQ ID No. 75),a light chain variable region CDR2 comprising KVS (SEQ ID No. 76) and a light chain variable region comprising SQSTHVPYT (SEQ ID No. 77). 
     
     
         13 : The apheresis device according to  claim 12 , wherein the antibody is the monoclonal antibody M1D1. 
     
     
         14 : The apheresis device according to  claim 1 , wherein the carrier is a sterile and pyrogen-free column. 
     
     
         15 : The apheresis device according to  claim 1 , comprising at least two different HTT-binding molecules.